All Title Author
Keywords Abstract

PLOS ONE  2012 

Novel Levamisole Derivative Induces Extrinsic Pathway of Apoptosis in Cancer Cells and Inhibits Tumor Progression in Mice

DOI: 10.1371/journal.pone.0043632

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Levamisole, an imidazo(2,1-b)thiazole derivative, has been reported to be a potential antitumor agent. In the present study, we have investigated the mechanism of action of one of the recently identified analogues, 4a (2-benzyl-6-(4′-fluorophenyl)-5-thiocyan?ato-imidazo[2,1-b][1], [3], [4]thiadiazole). Materials and Methods ROS production and expression of various apoptotic proteins were measured following 4a treatment in leukemia cell lines. Tumor animal models were used to evaluate the effect of 4a in comparison with Levamisole on progression of breast adenocarcinoma and survival. Immunohistochemistry and western blotting studies were performed to understand the mechanism of 4a action both ex vivo and in vivo. Results We have determined the IC50 value of 4a in many leukemic and breast cancer cell lines and found CEM cells most sensitive (IC50 5 μM). Results showed that 4a treatment leads to the accumulation of ROS. Western blot analysis showed upregulation of pro-apoptotic proteins t-BID and BAX, upon treatment with 4a. Besides, dose-dependent activation of p53 along with FAS, FAS-L, and cleavage of CASPASE-8 suggest that it induces death receptor mediated apoptotic pathway in CEM cells. More importantly, we observed a reduction in tumor growth and significant increase in survival upon oral administration of 4a (20 mg/kg, six doses) in mice. In comparison, 4a was found to be more potent than its parental analogue Levamisole based on both ex vivo and in vivo studies. Further, immunohistochemistry and western blotting studies indicate that 4a treatment led to abrogation of tumor cell proliferation and activation of apoptosis by the extrinsic pathway even in animal models. Conclusion Thus, our results suggest that 4a could be used as a potent chemotherapeutic agent.

References

[1]  Nambiar M, Kari V, Raghavan SC (2008) Chromosomal translocations in cancer. Biochim Biophys Acta 1786: 139–152.
[2]  Nickoloff JA, De Haro LP, Wray J, Hromas R (2008) Mechanisms of leukemia translocations. Curr Opin Hematol 15: 338–345.
[3]  Aplan PD (2005) “You break it, you fix it.”. Blood 105: 1843–1844.
[4]  Rowley JD (2001) Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer 1: 245–250.
[5]  Nambiar M, Raghavan SC (2011) How does DNA break during chromosomal translocations? Nucleic Acids Res 39: 5813–5825.
[6]  Raghavan SC, Swanson PC, Wu X, Hsieh CL, Lieber MR (2004) A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature 428: 88–93.
[7]  Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2008) Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8: 497–511.
[8]  Nussenzweig A, Nussenzweig MC (2010) Origin of chromosomal translocations in lymphoid cancer. Cell 141: 27–38.
[9]  Moen MD, McKeage K, Plosker GL, Siddiqui MA (2007) Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 67: 299–320.
[10]  Robert J, Jarry C (2003) Multidrug resistance reversal agents. J Med Chem 46: 4805–4817.
[11]  Huang C, Yang S, Ge R, Sun H, Shen F, et al. (2008) ZNF23 induces apoptosis in human ovarian cancer cells. Cancer Lett 266: 135–143.
[12]  Tang DG, Porter AT (1997) Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 32: 284–293.
[13]  Buolamwini JK (2000) Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 6: 379–392.
[14]  Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR (1991) Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 9: 2052–2066.
[15]  Kovach JS, Svingen PA, Schaid DJ (1992) Levamisole potentiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatase. J Natl Cancer Inst 84: 515–519.
[16]  Friis T, Engel AM, Klein BM, Rygaard J, Houen G (2005) Levamisole inhibits angiogenesis in vitro and tumor growth in vivo. Angiogenesis 8: 25–34.
[17]  Guminska M, Kedryna T, Marchut E (1986) The effect of levamisole on energy metabolism in Ehrlich ascites tumour cells in vitro. Biochem Pharmacol 35: 4369–4374.
[18]  Artwohl M, Holzenbein T, Wagner L, Freudenthaler A, Waldhausl W, et al. (2000) Levamisole induced apoptosis in cultured vascular endothelial cells. Br J Pharmacol 131: 1577–1583.
[19]  Andreani A, Bonazzi D, Rambaldi M (1982) Heterocyclisierungen unter Verwendung cyclischer Hydrazinium- und Hydrazoniumdithiokohlens?urediester-Salz?ezu zwei- und dreikernigen S,N-Heterocyclen. Archiv der Pharmazie 315: 451–456.
[20]  Gadad AK, Karki SS, Rajurkar VG, Bhongade BA (1999) Synthesis and biological evaluation of 5-formyl-6-arylimidazo(2,1-b)-1,3,4-thia?diazole-2-N-(dimethylaminomethino) sulfonamides as antitumor agents. Arzneimittelforschung 49: 858–863.
[21]  Karki SS, Panjamurthy K, Kumar S, Nambiar M, Ramareddy SA, et al. (2011) Synthesis and biological evaluation of novel 2-aralkyl-5-substituted-6-(4′-fluorophen?yl)-imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent anticancer agents. Eur J Med Chem 46: 2109–2116.
[22]  Shahabuddin MS, Nambiar M, Moorthy BT, Naik PL, Choudhary B, et al. (2011) A novel structural derivative of natural alkaloid ellipticine, MDPSQ, induces necrosis in leukemic cells. Invest New Drugs 29: 523–533.
[23]  Chiruvella KK, Kari V, Choudhary B, Nambiar M, Ghanta RG, et al. (2008) Methyl angolensate, a natural tetranortriterpenoid induces intrinsic apoptotic pathway in leukemic cells. FEBS Lett 582: 4066–4076.
[24]  Korzeniewski C, Callewaert DM (1983) An enzyme-release assay for natural cytotoxicity. J Immunol Methods 64: 313–320.
[25]  Chiruvella KK, Raghavan SC (2011) A natural compound, methyl angolensate, induces mitochondrial pathway of apoptosis in Daudi cells. Invest New Drugs 4: 583–592.
[26]  Noaman E, Badr El-Din NK, Bibars MA, Abou Mossallam AA, Ghoneum M (2008) Antioxidant potential by arabinoxylan rice bran, MGN-3/biobran, represents a mechanism for its oncostatic effect against murine solid Ehrlich carcinoma. Cancer Lett 268: 348–359.
[27]  Ghosh M, Bhattacharya S, Sadhu U, Dutta S, Sanyal U (1997) Evaluation of beta-tethymustine, a new anticancer compound, in murine tumour models. Cancer Lett 119: 7–12.
[28]  Attia MA, Weiss DW (1966) Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26: 1787–1800.
[29]  Sharma S, Panjamurthy K, Choudhary B, Srivastava M, Shahabuddin M, et al. (2012) A novel DNA intercalator, 8-methoxy pyrimido[4′,5′:4,5]thieno (2,3-b)quinoline-4(3H)-one induces apoptosis in cancer cells, inhibits the tumor progression and enhances lifespan in mice with tumor. Mol Carcinog
[30]  Bhattacharyya A, Choudhuri T, Pal S, Chattopadhyay S, Datta KG, et al. (2003) Apoptogenic effects of black tea on Ehrlich's ascites carcinoma cell. Carcinogenesis 24: 75–80.
[31]  Hazra B, Kumar B, Biswas S, Pandey BN, Mishra KP (2005) Enhancement of the tumour inhibitory activity, in vivo, of diospyrin, a plant-derived quinonoid, through liposomal encapsulation. Toxicol Lett 157: 109–117.
[32]  Kumagai H, Mukaisho K, Sugihara H, Miwa K, Yamamoto G, et al. (2004) Thioproline inhibits development of esophageal adenocarcinoma induced by gastroduodenal reflux in rats. Carcinogenesis 25: 723–727.
[33]  Vrekoussis T, Chaniotis V, Navrozoglou I, Dousias V, Pavlakis K, et al. (2009) Image analysis of breast cancer immunohistochemistry-stained sections using ImageJ: an RGB-based model. Anticancer Res 29: 4995–4998.
[34]  Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481–490.
[35]  Luppi G, Zoboli A, Barbieri F, Crisi G, Piccinini L, et al. (1996) Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma. Ann Oncol 7: 412–415.
[36]  Symoens J, Veys E, Mielants M, Pinals R (1978) Adverse reactions to levamisole. Cancer Treat Rep 62: 1721–1730.
[37]  Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, et al. (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715.
[38]  Cheung AN, Ngan HY, Chen WZ, Loke SL, Collins RJ (1993) The significance of proliferating cell nuclear antigen in human trophoblastic disease: an immunohistochemical study. Histopathology 22: 565–568.
[39]  Sugimoto Y, Konoki K, Murata M, Matsushita M, Kanazawa H, et al. (2009) Design, synthesis, and biological evaluation of fluorinated analogues of salicylihalamide. J Med Chem 52: 798–806.
[40]  Kumar A, D'Souza SS, Nagaraj SR, Gaonkar SL, Salimath BP, et al. (2009) Antiangiogenic and antiproliferative effects of substituted-1,3,4-oxadiazole derivatives is mediated by down regulation of VEGF and inhibition of translocation of HIF-1alpha in Ehrlich ascites tumor cells. Cancer Chemother Pharmacol 64: 1221–1233.
[41]  Gekeler V, Epple J, Kleymann G, Probst H (1993) Selective and synchronous activation of early-S-phase replicons of Ehrlich ascites cells. Mol Cell Biol 13: 5020–5033.
[42]  Wiebke EA, Grieshop NA, Loehrer PJ, Eckert GJ, Sidner RA (2003) Antitumor effects of 5-fluorouracil on human colon cancer cell lines: antagonism by levamisole. J Surg Res 111: 63–69.
[43]  Salem FS, Badr MO, Neamat-Allah AN (2011) Biochemical and pathological studies on the effects of levamisole and chlorambucil on Ehrlich ascites carcinoma-bearing mice. Vet Ital 47: 89–95.
[44]  Ramanadham M, Nageshwari B (2010) Anti-proliferative effect of levamisole on human myeloma cell lines in vitro. J Immunotoxicol 7: 327–332.
[45]  Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
[46]  Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR (1998) The p53 network. J Biol Chem 273: 1–4.
[47]  Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293–299.
[48]  Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, et al. (1998) Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 95: 4997–5002.
[49]  Rosse T, Olivier R, Monney L, Rager M, Conus S, et al. (1998) Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 391: 496–499.
[50]  Yu J, Zhang L (2008) PUMA, a potent killer with or without p53. Oncogene 27 Suppl 1: S71–83.
[51]  Li PF, Dietz R, von Harsdorf R (1999) p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 18: 6027–6036.
[52]  Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, et al. (2012) p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis. Cell 149: 1536–1548.
[53]  Sallmyr A, Tomkinson AE, Rassool FV (2008) Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. Blood 112: 1413–1423.
[54]  Kumar TS, Kari V, Choudhary B, Nambiar M, Akila TS, et al. (2010) Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells. J Biol Chem 285: 32657–32670.
[55]  Durland-Busbice S, Reisman D (2002) Lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the gene. Leukemia 16: 2165–2167.
[56]  Knudson CM, Korsmeyer SJ (1997) Bcl-2 and Bax function independently to regulate cell death. Nat Genet 16: 358–363.
[57]  Tsujimoto Y (1998) Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 3: 697–707.
[58]  Chai J, Du C, Wu JW, Kyin S, Wang X, et al. (2000) Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406: 855–862.

Full-Text

comments powered by Disqus